Cargando…
Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review
Pulmonary sarcomatoid carcinoma (PSC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its unfavorable prognosis. Previous studies have elucidated that PSC generally exhibits a significant expression of programmed death-ligand 1 (PD-L1), an elevated tumor mutation burden, and...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618617/ https://www.ncbi.nlm.nih.gov/pubmed/37920159 http://dx.doi.org/10.3389/fonc.2023.1241475 |
_version_ | 1785129815971463168 |
---|---|
author | Wen, Yingmei Dong, Yi Yi, Lina Yang, Guifang Xiao, Mengxia Li, Qingqing Zhao, Chen Ye, Dafu Yao, Yi |
author_facet | Wen, Yingmei Dong, Yi Yi, Lina Yang, Guifang Xiao, Mengxia Li, Qingqing Zhao, Chen Ye, Dafu Yao, Yi |
author_sort | Wen, Yingmei |
collection | PubMed |
description | Pulmonary sarcomatoid carcinoma (PSC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its unfavorable prognosis. Previous studies have elucidated that PSC generally exhibits a significant expression of programmed death-ligand 1 (PD-L1), an elevated tumor mutation burden, and marked vascular invasion. These factors imply the possible effectiveness of treatments like immunotherapy and anti-angiogenic therapy. The subject of this case was a 65-year-old male diagnosed with advanced PSC, characterized by high PD-L1 expression and devoid of known driver gene mutations. Owing to the restrictions imposed by the COVID-19 pandemic, the patient initially underwent home-based treatment with anlotinib, which led to symptomatic improvement after a single treatment cycle. Subsequent hospitalization allowed for the administration of anlotinib plus Pembrolizumab, resulting in a partial response. Radiotherapy was necessitated due to local disease progression. But after 15 cycles of treatment with Pembrolizumab, hyperprogression was observed. The patient’s overall survival spanned 14 months, with no evident adverse reactions to the medications. Genomic analysis revealed potential associations between treatment efficacy and mutations in the TP53, NF1, and MET genes. This case underscores the effectiveness and safety of a first-line treatment regimen combining pan-target anti-angiogenic therapy (anlotinib) with anti-tumor immunotherapy. |
format | Online Article Text |
id | pubmed-10618617 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106186172023-11-02 Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review Wen, Yingmei Dong, Yi Yi, Lina Yang, Guifang Xiao, Mengxia Li, Qingqing Zhao, Chen Ye, Dafu Yao, Yi Front Oncol Oncology Pulmonary sarcomatoid carcinoma (PSC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its unfavorable prognosis. Previous studies have elucidated that PSC generally exhibits a significant expression of programmed death-ligand 1 (PD-L1), an elevated tumor mutation burden, and marked vascular invasion. These factors imply the possible effectiveness of treatments like immunotherapy and anti-angiogenic therapy. The subject of this case was a 65-year-old male diagnosed with advanced PSC, characterized by high PD-L1 expression and devoid of known driver gene mutations. Owing to the restrictions imposed by the COVID-19 pandemic, the patient initially underwent home-based treatment with anlotinib, which led to symptomatic improvement after a single treatment cycle. Subsequent hospitalization allowed for the administration of anlotinib plus Pembrolizumab, resulting in a partial response. Radiotherapy was necessitated due to local disease progression. But after 15 cycles of treatment with Pembrolizumab, hyperprogression was observed. The patient’s overall survival spanned 14 months, with no evident adverse reactions to the medications. Genomic analysis revealed potential associations between treatment efficacy and mutations in the TP53, NF1, and MET genes. This case underscores the effectiveness and safety of a first-line treatment regimen combining pan-target anti-angiogenic therapy (anlotinib) with anti-tumor immunotherapy. Frontiers Media S.A. 2023-10-18 /pmc/articles/PMC10618617/ /pubmed/37920159 http://dx.doi.org/10.3389/fonc.2023.1241475 Text en Copyright © 2023 Wen, Dong, Yi, Yang, Xiao, Li, Zhao, Ye and Yao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wen, Yingmei Dong, Yi Yi, Lina Yang, Guifang Xiao, Mengxia Li, Qingqing Zhao, Chen Ye, Dafu Yao, Yi Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review |
title | Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review |
title_full | Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review |
title_fullStr | Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review |
title_full_unstemmed | Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review |
title_short | Anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review |
title_sort | anlotinib combined with pembrolizumab as first-line treatment for advanced pulmonary sarcomatoid carcinoma: a case report and literature review |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618617/ https://www.ncbi.nlm.nih.gov/pubmed/37920159 http://dx.doi.org/10.3389/fonc.2023.1241475 |
work_keys_str_mv | AT wenyingmei anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview AT dongyi anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview AT yilina anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview AT yangguifang anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview AT xiaomengxia anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview AT liqingqing anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview AT zhaochen anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview AT yedafu anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview AT yaoyi anlotinibcombinedwithpembrolizumabasfirstlinetreatmentforadvancedpulmonarysarcomatoidcarcinomaacasereportandliteraturereview |